1. Introduction {#sec1}
===============

Human airway epithelium is a pseudostratified layer consisting of basal cells, secretory cells, and columnar ciliated cells. The epithelium provides a critical interface between the body and the external environment ([@bib7]). This epithelial layer is known to be necessary for host defense against inhaled particles and microbes. The layer serves as a physical barrier, secretes factors that mediate immunity, inflammation, and antioxidant defense, and clears materials through a mucociliary pathway ([@bib12]; [@bib13]; [@bib21]; [@bib40]).

Generally, primary cell models are more representative of cells *in vivo*, compared with cancer-derived cell lines ([@bib28]; [@bib49]). Well-established organ-like primary cell models are more useful in investigating the functional properties of intact organs under normal or diseased conditions because these cells are likely to be more physiologically comparable to organs *in vivo* ([@bib51]). In air-liquid interface (ALI) culture, un-differentiated normal human primary bronchial/tracheal epithelial (UD) cells can form a pseudostratified cell layer much like they do *in vivo* ([@bib11]). This well-differentiated normal human primary bronchial/tracheal epithelial (WD) cell model better mimics the *in vivo* environment than submersion culture which inhibits ciliogenesis and mucociliary movement ([@bib28]; [@bib31]). The WD cell model has been used for *in vitro* studies of drug pharmacokinetics and to study lung diseases such as asthma, chronic obstructive pulmonary disease and cystic fibrosis ([@bib1]; [@bib11]; [@bib14]; [@bib15]; [@bib16]; [@bib36]; [@bib41]; [@bib58]). However, structural and proteomic differences between WD and UD cells remains to be characterized.

In the current study, we investigated the proteomic profiles of WD cells and UD cells using label-free Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS). Our results can inform research on host pathogen infection and defense, external particle transport and clearance, and signal transduction.

2. Materials and methods {#sec2}
========================

2.1. Cell culture {#sec2.1}
-----------------

Normal human primary bronchial/tracheal epithelial cells which derived from an 8-year-old female with bacteria, yeast, fungi, *mycoplasma*, hepatitis B, hepatitis C and HIV testing negative were purchased from Lifeline (Passage \#1, Lifeline, Frederick, MD, USA). Cells were cultured and passaged according to instructions provided by the supplier. Briefly, cells were thawed in a 37 °C water bath and cultivated in 75 cm^2^ flasks with serum-free growth media (BronchiaLife B/T complete medium, Lifeline, USA) at 37 °C, 5% CO~2~. Actively proliferating cells were passaged when at 70%--80% confluence. Passage \#4 un-differentiated cells were divided into two parts, one was used for ALI culture, and the other was still used for submersion culture to obtain WD and UD cells samples for subsequent analysis, respectively.

Briefly, WD cells were grown at the ALI by seeding 5--8×10^4^ Passage \#4 UD cells on collagen-coated transwell inserts (0.3 cm^2^, 0.4 μm pore size, BD-Falcon, Tewksbury, MA, USA) in 24-well plates at 37 °C, 5% CO~2~. Following 24 h of incubation, the medium in the apical chamber was removed by aspiration. Differentiation medium (Dulbecco\'s Modified Eagle Medium: Nutrient Mixture F-12 (DMEM:F12) containing 2% Ultroser G serum substitute (Pall BioSepra, Cergy-Staint-Christophe, France)) was added to the basolateral chamber as previously reported ([@bib17]). Differentiation medium was replaced every 2 days, and WD cells were evaluated following 21 days of culture. UD cell samples were grown in submersion culture in three T75 flasks to 100% confluence prior to harvest for analysis.

2.2. Transepithelial electrical resistance (TEER) measurement {#sec2.2}
-------------------------------------------------------------

During culture of WD cells in differentiation medium, the polarity of cells was determined by TEER measurement. The apical and basolateral chambers of inserts were filled with fresh differentiation medium following 21 days of ALI culture, and equilibrated at 37 °C, 5% CO2 for 10 min. TEER values were determined using two Millicell-ERS (MERS00002, Millipore, Burlington, MA, USA) electrodes submerged into the insert medium. WD cells with TEER values \> 1000 Ω cm^2^ were considered well-differentiated and met the requirement for subsequent studies of the model ([@bib16]; [@bib17]; [@bib28]).

2.3. Immunofluorescence assay for WD cells biomarkers Zona occludens-1 and β-tubulin IV {#sec2.3}
---------------------------------------------------------------------------------------

To further confirm differentiation of WD cells, two differentiation biomarkers --- tight junction protein Zona occludens-1 (ZO-1) and cilia marker β-tubulin IV --- were quantified by immunofluorescence assay (IFA) ([@bib17]). Following 21 days of ALI culture, WD cells on insert membranes were fixed with cold absolute ethanol for 20 min. Fixed membranes were cut into several small pieces, washed in PBS three times for 5 min, and permeabilized with 0.2% Triton X-100 for 15 min at room temperature. Membranes were blocked with 10% goat serum for 30 min at room temperature, then incubated overnight at 4 °C with primary ZO-1 (\#13663, CST, Danvers, MA, USA) and β-tubulin IV (ab179509, Abcam, Cambridge, MA, USA) antibody diluted 1:200 and 1:400 in PBS plus 2% goat serum, respectively. Subsequently, membranes were incubated with a fluorescein Alexa fluor 488-conjugated secondary antibody (\#4412, CST). Confocal images were captured using a D-Eclipse C1 confocal microscope (Nikon, Melville, NY, USA) controlled by Nikon EZ-C1 software.

2.4. Sample preparation for label-free LC-MS/MS experiments {#sec2.4}
-----------------------------------------------------------

Media was removed from UD and WD cells cultures, and cells were washed twice with HBSS. A total of 500 μl lysis buffer (4% SDS, 100 mM DTT, 150 mM Tris-HCl pH 8.0) was added to each T75 flask containing UD cells. Cells were then scraped and collected. UD cells from three T75 flasks were used for label-free LC-MS/MS experiments. Transwell inserts containing WD cells (0.3 cm^2^) with TEER values \> 1000 Ω cm^2^ were collected. Eleven inserts of WD cells were torn off and placed together into 150 μl of lysis buffer. A total of 3 × 11 inserts of WD cells were used for label-free LC-MS/MS. Post-addition of lysis buffer, UD and WD cells were disrupted using a homogenizer (Fastprep-24®, MP Biomedical, Solon, OH, USA), then boiled for 5 min. Resulting homogenates were ultrasonicated and boiled again for 5 min. Undissolved cellular debris was removed by centrifugation at 14000 rpm for 15 min. The supernatant was collected and quantified with a BCA Protein Assay Kit (Bio-Rad, USA). Protein digestion (250 μg for each sample) was performed according to the FASP procedure described by Wisniewski, Zougman et al. ([@bib56]). Briefly, DTT and other low-molecular-weight components of the lysis buffer were removed by repeated centrifuge-facilitated ultrafiltration (Microcon units, 30 kD) using 200 μl of UA buffer (8 M Urea, 150 mM Tris-HCl, pH 8.0). Reduced cysteine residues were then blocked by incubating for 20 min with 100 μl of 0.05 M iodoacetamide in UA buffer in darkness. Filters were washed three times with 100 μl of UA buffer, then twice with 100 μl of 25 mM NH~4~HCO~3~. Finally, the protein suspension was digested overnight at 37 °C with 3 μg trypsin (Promega) in 40 μl of 25 mM NH~4~HCO~3~. Resulting peptides were collected as a filtrate and measured by UV light spectral density at 280 nm. Peptide content was calculated using an extinction coefficient on the basis of tryptophan and tyrosine frequency in vertebrate proteins.

2.5. Q exactive LC-MS/MS analysis {#sec2.5}
---------------------------------

Peptide samples were desalted on C18 Cartridges (Empore™ SPE Cartridges C18 (standard density), bed I.D. 7 mm, volume 3 ml, Sigma), then concentrated by vacuum centrifugation and reconstituted in 40 μl of 0.1% (v/v) trifluoroacetic acid. MS experiments were performed on a Q Exactive mass spectrometer coupled to an Easy nLC (Proxeon Biosystems, now Thermo Fisher Scientific). Five μg of peptide were loaded onto a C18-reversed phase column (Thermo Scientific Easy Column, 10 cm long, 75 μm inner diameter, 3 μm resin) in buffer A (2% acetonitrile, 0.1% formic acid) and separated with a linear gradient of buffer B (80% acetonitrile, 0.1% formic acid). The flow rate was controlled by IntelliFlow technology at 250 nL/min over 120 min. MS data were acquired using a data-dependent top10 method dynamically choosing the most abundant precursor ions from the higher-energy collisional dissociation (HCD) fragmentation survey scan (300--1800 m/z). Target value was determined by predictive Automatic Gain Control (pAGC). Dynamic exclusion duration was 25 s. Survey scans were acquired at a resolution of 70,000 at m/z 200 and the resolution for HCD spectra was set to 17,500 at 200 m/z. Normalized collision energy was 30 eV and the underfill ratio, which specifies the minimum target value percentage likely to be reached at maximum fill time, was defined as 0.1%. The instrument was run with peptide recognition mode enabled.

2.6. Sequence database searching and data analysis {#sec2.6}
--------------------------------------------------

MS data were analyzed using MaxQuant software version 1.3.0.5. MS data were searched against the UniProtKB Homo Sapiens database (3,024,653 total entries, downloaded on 12/09/17). An initial search was set at a precursor mass window of 6 parts-per-million (ppm). The search followed an enzymatic cleavage rule of Trypsin/P and allowed for a maximum of two missed cleavage sites and a mass tolerance of 20 ppm for fragment ions. Carbamidomethylation of cysteine was defined as fixed modification, while protein N-terminal acetylation and methionine oxidation were defined as variable modifications for database searches. The cutoff global false discovery rate (FDR) for peptide and protein identification was set to 0.01. Label-free quantification was carried out in MaxQuant as previously described ([@bib42]). Protein abundance was calculated based on normalized spectral protein intensity (LFQ intensity) ([@bib25]).

2.7. Imputation of missing intensity values {#sec2.7}
-------------------------------------------

Original quantitative protein intensities were converted to base 2 logarithms (log~2~). Missing values in the quantification were imputed by two methods. First, intensity values of the two groups were processed separately. For a protein with missing values in a group, if at least one sample had a quantitative value in the same group, the missing values were imputed using the K nearest neighbors (KNN) method ([@bib50]). Proteins with missing values in all samples of one group remained. These missing values were imputed using the random tail imputation (RTI) method ([@bib10]) using Persues software set to "Replace missing values from normal distribution" ([@bib52]) (Width = 0.3, Down shift = 1.8). The KNN method assumes that missing intensity values result from an unknown and complex combination of random processes and the values are imputed based on measured intensities in other samples from the same group. The RTI method assumes that low abundance proteins are close to the limit of detection of the instrument. Missing values are drawn from the tail of a truncated normal distribution, representative of proteins that are in low abundance ([@bib22]; [@bib55]).

2.8. Identification of up/down-regulated proteins {#sec2.8}
-------------------------------------------------

Log~2~ intensities, with imputed values, were converted to original numbers by multiplying by two. For each protein, the fold change ratio was computed by dividing average intensity of WD cells by average intensity of UD cells. Ratios and mean intensity values of all six samples were fed into Persues significance B analysis to identify significant outlier ratios ([@bib6]). By computing FDR based on significance B, proteins with a Benjamini-Hochberg corrected p-value threshold of 0.05 were defined as up/down-regulated proteins.

2.9. Expression profile analysis {#sec2.9}
--------------------------------

Gene ontology (GO) IDs and KEGG orthology (KO) IDs of proteins were obtained by querying the UniProtKB database ([@bib53]). The GO and KO IDs were used to classify proteins into categories ([@bib2]; [@bib48]) and KEGG pathways ([@bib19]; [@bib20]), respectively. The number of proteins in each classification was counted. Fisher\'s and chi-square tests were used to assess significance. Categories and pathways with a greater percent of proteins up or down regulated relative to the full protein set and with a Fisher\'s p \< 0.05, were considered significant. The enrichment factor (EF) was expressed as follow (1):

Where Entry equals the number of proteins in a classification category, Whole equals the number of proteins in the entire functional classification system, DIFSet equals the up/down-regulated protein set and EntireSet equals the entire protein set. The UniProtKB protein accession number was used to query STRING ([@bib47]) to identify interaction relationships between pairs of up/down-regulated proteins. Each protein was manually confirmed by a combination of protein name and protein description. The network of interaction relationships was illustrated by R package graph ([@bib8]).

2.10. Confirmation of differentially expressed proteins by liquid chromatography parallel reaction monitoring mass spectrometry (LC-PRM/MS) {#sec2.10}
-------------------------------------------------------------------------------------------------------------------------------------------

To confirm the differentially expressed proteins identified by label-free analysis, the expression levels of selected proteins were further quantified by LC-PRM/MS analysis ([@bib35]). Briefly, UD and WD cell samples were collected and lysed as previously described. Peptides were prepared according to the label free protocol. Each sample was then spiked with an AQUA stable isotope peptide as an internal reference standard. Tryptic peptides were loaded on C18 stage tips for desalting prior to reversed-phase chromatography on an Easy nLC-1200 system (Thermo Scientific). LC gradients were run for 45 min with acetonitrile ranging from 5 to 35%. PRM analysis was performed on a Q Exactive Plus mass spectrometer (Thermo Scientific). Optimized collision energy, charge state, and retention times of the most significantly regulated peptides were generated experimentally using unique high intensity peptides and high confidence target proteins. The mass spectrometer was operated in positive ion mode, with the following parameters: The full MS1 scan was acquired with a resolution of 70000 (at 200 m/z), automatic gain control (ACG) target values of 3.0 × 10^−6^, and 250 ms maximum ion injection time. Full MS scans were followed by 20 PRM scans at 35000 resolution (at 200 m/z), AGC of 3.0 × 10^−6^ and 200 ms maximum injection time. Targeted peptides were isolated with a 2 THz window. Ion activation/dissociation was performed at normalized collision energy of 27 in an HCD collision cell. Raw data were analyzed using Skyline (MacCoss Lab, University of Washington) ([@bib26]). Signal intensities of individual peptide sequences for each significantly altered protein was quantified relative to each sample and normalized to a standard reference.

2.11. Statistical analysis {#sec2.11}
--------------------------

Significance B measure was used to identify up/down-regulated proteins in WD cells versus UD cells. T-tests were used to analyze LC-PRM/MS data, and confirm significant protein-expression differences between WD cells and UD cells. Fisher\'s and chi-square tests were used to detect the significance of enriched GO categories and KEGG pathways.

3. Results {#sec3}
==========

3.1. Cell and sample preparation for label-free LC-MS/MS {#sec3.1}
--------------------------------------------------------

A total of 33 WD cell inserts were cultured at ALI for 21 days. Mean TEER value was 1997 ± 454 Ω cm^2^, and each insert\'s TEER value was greater than 1000 Ω cm^2^. Expression of the biomarkers ZO-1 and β-tubulin IV was used to confirm differentiation to WD cells ([Figure 1](#fig1){ref-type="fig"}). Inserts were divided into 3 so that 11 inserts represented one sample. For UD cells, one T75 flask of cells represented one sample and three samples were evaluated. Lysis and extraction yielded a total of 337 ± 27 μg and 1385 ± 45 μg proteins from WD and UD cells, respectively. Proteins were digested and used for LC-MS/MS.Figure 1Immunofluorescence analysis of the tight junction marker ZO-1 and the cilia marker β-tubulin IV of well-differentiated normal human primary bronchial/tracheal epithelial cells. Well-differentiated normal human primary bronchial/tracheal epithelial cells were stained with anti-ZO-1 (A) or anti-β-tubulin IV antibody (B). Images were captured using a confocal microscope. Controls were stained with no primary antibody. Nuclei were stained with DAPI (blue).Figure 1

3.2. Data correlation, principal component analysis (PCA) and up/down-regulated proteins {#sec3.2}
----------------------------------------------------------------------------------------

MS data analysis of the six samples identified 3,579 proteins after filtering out potential contaminating proteins. Log~2~ intensities, including imputed values, showed near normal distribution. Missing values imputed by the RTI method were distributed in areas of low intensity. These missing values existed in all samples within a group and were assumed to be due to low protein abundance ([Figure S1](#appsec1){ref-type="sec"}). Pearson correlation coefficients were computed for every binary sample comparison. Within group correlation coefficients were greater than between group comparisons (r = 0.9744--0.9792 vs. r = 0.7508--0.7581) ([Figure S2](#appsec1){ref-type="sec"}).

PCA was used to investigate the characteristics of abundant proteins identified in the 6 samples ([Figure 2](#fig2){ref-type="fig"}). Samples were plotted on a two-dimensional plane based on the coordinates obtained from the first and second principal components. Samples from the two cell types separated from each other along the x-axis (PCA1). This separation along the first principal component was observed regardless of whether the input data excluded missing values ([Figure 2](#fig2){ref-type="fig"}A) or consisted of all values, including imputed intensities ([Figure 2](#fig2){ref-type="fig"}B).Figure 2The first and second principal components derived from PCA of un-differentiated normal human primary bronchial/tracheal epithelial cells and well-differentiated cells. Percentages in parentheses represent the proportion of variances for PC1 or PC2. (A) Proteins with missing intensity values in any of the 6 samples were excluded. (B) All identified proteins were used after the imputation of missing values; UD and WD: un-differentiated and well-differentiated normal human primary bronchial/tracheal epithelial cells.Figure 2

The ratios of protein fold changes between the two groups were investigated by significance B measure ([Figure 3](#fig3){ref-type="fig"}). Proteins with significant fold changes appear in both high and low ratio regions. The boundaries between proteins of different significance ranges were not on a vertical line since significance B was weighted by signal intensity. Proteins with p \< 0.05 and FDR\<0.05 (red dots) were considered to be up/down-regulated proteins in this study. There were 198 such proteins, 121 (61.1%) of which were up-regulated ([Table 1](#tbl1){ref-type="table"}) and 77 (38.9%) down-regulated ([Table 2](#tbl2){ref-type="table"}) in WD cells compared with UD cells.Figure 3Proteome-wide quantification and significant fold change in well-differentiated normal human primary bronchial/tracheal epithelial cells compared with un-differentiated cells. Each dot represents a protein. The X-axis is the Log~10~ ratio obtained by dividing the mean of each protein\'s value in well-differentiated normal human primary bronchial/tracheal epithelial cells by its value in un-differentiated cells. FDR = false discovery rate.Figure 3Table 1Up-regulated proteins in well-differentiated normal human primary bronchial/tracheal epithelial cells compared with un-differentiated cells.Table 1Serial numberUniProtKB accessionProtein nameMean intensityLog10 (Ratio)p ValueFDRProtein description1[Q92817](ncbi-p:Q92817){#intref0015}EVPL2.2630E+103.20908.7280E-141.0412E-10Envoplakin2[Q6UWP8](ncbi-p:Q6UWP8){#intref0020}SBSN6.2868E+093.00912.5710E-121.5336E-09Suprabasin3[O43251](ncbi-p:O43251){#intref0025}RBFOX26.4577E+092.95136.5859E-122.9504E-09RNA binding protein fox-1 homolog 24[Q9UBG3](ncbi-p:Q9UBG3){#intref0030}CRNN7.0967E+092.87572.1926E-118.7191E-09Cornulin5[P00966](ncbi-p:P00966){#intref0035}ASS14.6387E+092.82165.0932E-111.8228E-08Argininosuccinate synthase6[A8K2U0](uniprotkb:A8K2U0){#intref0040}A2ML19.3797E+092.79587.5706E-112.2429E-08Alpha-2-macroglobulin-like protein 17[P07476](ncbi-p:P07476){#intref0045}IVL2.0278E+102.78658.7285E-112.2429E-08Involucrin8[Q6ZVX7](ncbi-p:Q6ZVX7){#intref0050}NCCRP14.3506E+092.78249.2840E-112.2429E-08F-box only protein 509[P01024](ncbi-p:P01024){#intref0055}C35.8033E+092.77651.0152E-102.2429E-08Complement C310[Q9UBC9](ncbi-p:Q9UBC9){#intref0060}SPRR31.7624E+102.77431.0499E-102.2429E-08Small proline-rich protein 311[P29508](ncbi-p:P29508){#intref0065}SERPINB31.4966E+102.73221.9824E-103.3785E-08Serpin B312[B2R853](uniprotkb:B2R853){#intref0070}4.7231E+092.64367.3169E-101.0475E-07highly similar to Homo sapiens keratin 6E (KRT6E)13[P15941](ncbi-p:P15941){#intref0075}MUC13.8921E+092.63598.1770E-101.1091E-07Mucin-114[O95171](ncbi-p:O95171){#intref0080}SCEL5.2113E+092.62729.2712E-101.1851E-07Sciellin15[P80188](ncbi-p:P80188){#intref0085}LCN27.0981E+092.61341.1312E-091.3496E-07Neutrophil gelatinase-associated lipocalin16[P03973](ncbi-p:P03973){#intref0090}SLPI2.4978E+092.55872.1197E-121.5173E-09Antileukoproteinase17[P22735](ncbi-p:P22735){#intref0095}TGM15.6235E+092.42041.6425E-081.4696E-06Protein-glutamine gamma-glutamyltransferase K18[O00748](ncbi-p:O00748){#intref0100}CES21.9635E+092.35061.0653E-102.2429E-08Cocaine esterase19[Q96SN8](ncbi-p:Q96SN8){#intref0105}CDK5RAP21.1139E+092.34181.2474E-102.4803E-08CDK5 regulatory subunit-associated protein 220[B7ZLF8](uniprotkb:B7ZLF8){#intref0110}1.9555E+092.33141.5051E-102.8351E-08Uncharacterized protein21[P01833](ncbi-p:P01833){#intref0115}PIGR2.6257E+092.32641.6455E-102.9447E-08Polymeric immunoglobulin receptor22[Q9BYD5](ncbi-p:Q9BYD5){#intref0120}CNFN1.8270E+092.26265.0755E-108.0493E-08Cornifelin23[Q14CN2](ncbi-p:Q14CN2){#intref0125}CLCA41.9156E+092.26155.1728E-108.0493E-08Calcium-activated chloride channel regulator 424[Q9UBD6](ncbi-p:Q9UBD6){#intref0130}RHCG1.9540E+092.23378.3673E-101.1091E-07Ammonium transporter Rh type C25[P32926](ncbi-p:P32926){#intref0135}DSG33.0762E+092.18663.2491E-071.9710E-05Desmoglein-326[P0C870](ncbi-p:P0C870){#intref0140}JMJD77.3191E+082.18018.4130E-098.1379E-07JmjC domain-containing protein 727[Q8TE68](ncbi-p:Q8TE68){#intref0145}EPS8L11.2669E+092.16702.5945E-092.9018E-07Epidermal growth factor receptor kinase substrate 8-like protein 128[P07099](ncbi-p:P07099){#intref0150}EPHX15.7145E+092.15574.7195E-072.7244E-05Epoxide hydrolase 129[Q9H8H3](ncbi-p:Q9H8H3){#intref0155}METTL7A1.0383E+092.14583.6872E-093.7705E-07Methyltransferase-like protein 7A30[P19957](ncbi-p:P19957){#intref0160}PI31.1453E+092.13674.2885E-094.2635E-07Elafin31[P33121](ncbi-p:P33121){#intref0165}ACSL12.5380E+092.09099.0582E-098.5314E-07Long-chain-fatty-acid-CoA ligase 132[O00204](ncbi-p:O00204){#intref0170}SULT2B16.2752E+082.08203.8512E-082.9327E-06Sulfotransferase family cytosolic 2B member 133[P09758](ncbi-p:P09758){#intref0175}TACSTD23.3186E+092.07491.2247E-066.1733E-05Tumor-associated calcium signal transducer 234[C9JRL4](uniprotkb:C9JRL4){#intref0180}MDH16.3613E+082.05026.2117E-084.4464E-06Malate dehydrogenase, cytoplasmic35[O15020](ncbi-p:O15020){#intref0185}SPTBN21.3119E+092.03542.1974E-081.8725E-06Spectrin beta chain, non-erythrocytic 236[P00751](ncbi-p:P00751){#intref0190}CFB1.2925E+092.02672.5197E-082.0972E-06Complement factor B37[O43653](ncbi-p:O43653){#intref0195}PSCA1.0439E+092.01792.8935E-082.3205E-06Prostate stem cell antigen38[P40199](ncbi-p:P40199){#intref0200}CEACAM61.4252E+092.01742.9176E-082.3205E-06Carcinoembryonic antigen-related cell adhesion molecule 639[Q7L5L3](ncbi-p:Q7L5L3){#intref0205}GDPD31.1362E+092.01053.2449E-082.5246E-06Lysophospholipase D GDPD340[Q9NZT1](ncbi-p:Q9NZT1){#intref0210}CALML54.9035E+091.99902.9067E-061.3168E-04Calmodulin-like protein 541[Q9NQ38](ncbi-p:Q9NQ38){#intref0215}SPINK58.0895E+081.99561.3895E-079.5636E-06Serine protease inhibitor Kazal-type 542[Q8WWI1](ncbi-p:Q8WWI1){#intref0220}LMO71.1466E+091.99204.3241E-083.2242E-06LIM domain only protein 743[P35321](ncbi-p:P35321){#intref0225}SPRR1A2.3863E+101.98503.3994E-061.4658E-04Cornifin-A44[P02511](ncbi-p:P02511){#intref0230}CRYAB1.1546E+091.98095.1321E-083.7485E-06Alpha-crystallin B chain45[O60218](ncbi-p:O60218){#intref0235}AKR1B104.8585E+091.97483.8097E-061.6232E-04Aldo-keto reductase family 1 member B1046[B3KVV6](uniprotkb:B3KVV6){#intref0240}5.9357E+081.93693.2259E-071.9710E-05highly similar to Homo sapiens alpha-2-macroglobulin-like 1 (A2ML1)47[P51178](ncbi-p:P51178){#intref0245}PLCD13.2467E+081.92354.5173E-072.6504E-051-phosphatidylinositol 4,5-bisphosphate phosphodiesterase delta-148[P06731](ncbi-p:P06731){#intref0250}CEACAM52.5495E+091.92281.2376E-078.6848E-06Carcinoembryonic antigen-related cell adhesion molecule 549[Q13228](ncbi-p:Q13228){#intref0255}SELENBP18.5095E+081.90824.8299E-072.7439E-05Methanethiol oxidase50[Q14002](ncbi-p:Q14002){#intref0260}CEACAM71.1786E+091.89711.8142E-071.2251E-05Carcinoembryonic antigen-related cell adhesion molecule 751[O60437](ncbi-p:O60437){#intref0265}PPL4.8356E+101.88969.6145E-063.7813E-04Periplakin52[Q13835](ncbi-p:Q13835){#intref0270}PKP14.9289E+091.87451.1282E-054.3888E-04Plakophilin-153[P06702](ncbi-p:P06702){#intref0275}S100A91.5995E+111.86341.2687E-054.8826E-04Protein S100-A954[P30838](ncbi-p:P30838){#intref0280}ALDH3A12.2648E+101.85871.3318E-055.0174E-04Aldehyde dehydrogenase, dimeric NADP-preferring55[P57735](ncbi-p:P57735){#intref0285}RAB255.9955E+081.85071.0653E-065.6068E-05Ras-related protein Rab-2556[Q01995](ncbi-p:Q01995){#intref0290}TAGLN7.9855E+081.84541.1443E-065.8876E-05Transgelin57[Q5K634](ncbi-p:Q5K634){#intref0295}5.3396E+081.84491.1515E-065.8876E-05SCCA2/SCCA1 fusion protein isoform 158[P12277](ncbi-p:P12277){#intref0300}CKB1.0580E+091.84353.9578E-072.3608E-05Creatine kinase B-type59[Q5K684](ncbi-p:Q5K684){#intref0305}4.1629E+081.83131.5625E-067.5569E-05SCCA1/SCCA2 fusion protein60[T2F9S8](uniprotkb:T2F9S8){#intref0310}UPK3BL18.5360E+081.80801.8864E-069.0017E-05Uroplakin-3b-like protein 161[O14493](ncbi-p:O14493){#intref0315}CLDN47.0612E+081.80471.9711E-069.2825E-05Claudin-462[Q08AI8](ncbi-p:Q08AI8){#intref0320}C2orf544.7127E+081.77552.8922E-061.3168E-04Uncharacterized protein C2orf5463[P11684](ncbi-p:P11684){#intref0325}SCGB1A14.1025E+081.77383.2945E-061.4379E-04Uteroglobin64[O76027](ncbi-p:O76027){#intref0330}ANXA97.3907E+081.77043.0905E-061.3826E-04Annexin A965[Q14802](ncbi-p:Q14802){#intref0335}FXYD36.6276E+081.76913.1462E-061.3901E-04FXYD domain-containing ion transport regulator 366[Q99102](ncbi-p:Q99102){#intref0340}MUC42.3456E+091.75061.4571E-067.1440E-05Mucin-467[Q13510](ncbi-p:Q13510){#intref0345}ASAH13.7070E+091.74664.1852E-051.4131E-03Acid ceramidase68[P04233](ncbi-p:P04233){#intref0350}CD746.3419E+081.74514.2869E-061.8050E-04HLA class II histocompatibility antigen gamma chain69[Q8WVV4](ncbi-p:Q8WVV4){#intref0355}POF1B8.6002E+081.73344.9758E-062.0707E-04Protein POF1B70A0A1B0GVI3KRT104.0145E+081.71816.6414E-062.7011E-04Keratin, type I cytoskeletal 1071[P00352](ncbi-p:P00352){#intref0360}ALDH1A14.6622E+081.71316.4414E-062.6499E-04Retinal dehydrogenase 172[O60879](ncbi-p:O60879){#intref0365}DIAPH23.8248E+081.70587.7328E-063.0751E-04Protein diaphanous homolog 273[Q9BPW9](ncbi-p:Q9BPW9){#intref0370}DHRS94.5132E+081.70017.5849E-063.0501E-04Dehydrogenase/reductase SDR family member 974[P05109](ncbi-p:P05109){#intref0375}S100A86.6455E+101.66349.3945E-052.9237E-03Protein S100-A875[Q969L2](ncbi-p:Q969L2){#intref0380}MAL25.0317E+081.65711.2900E-054.9118E-04Protein MAL276[Q8N3Y7](ncbi-p:Q8N3Y7){#intref0385}SDR16C55.5245E+081.64921.4202E-055.2946E-04Epidermal retinol dehydrogenase 277[P24821](ncbi-p:P24821){#intref0390}TNC2.8193E+091.64721.0950E-043.3212E-03Tenascin78[Q99878](ncbi-p:Q99878){#intref0395}HIST1H2AJ4.0203E+081.62991.9310E-057.0521E-04Histone H2A type 1-J79[Q562Z4](ncbi-p:Q562Z4){#intref0400}ACT5.9844E+081.62511.9022E-057.0185E-04Actin-like protein80[P22532](ncbi-p:P22532){#intref0405}SPRR2D5.8401E+091.62461.3536E-044.0037E-03Small proline-rich protein 2D81[P22528](ncbi-p:P22528){#intref0410}SPRR1B4.1411E+091.59971.7035E-044.8774E-03Cornifin-B82[Q16762](ncbi-p:Q16762){#intref0415}TST6.0534E+081.57943.2663E-051.1674E-03Thiosulfate sulfurtransferase83[Q16610](ncbi-p:Q16610){#intref0420}ECM12.6063E+081.57273.7547E-051.3133E-03Extracellular matrix protein 184[B3KUB6](uniprotkb:B3KUB6){#intref0425}8.0577E+081.56034.0782E-051.3953E-03highly similar to Band 4.1-like protein 185[P09668](ncbi-p:P09668){#intref0430}CTSH4.4739E+081.56004.0936E-051.3953E-03Pro-cathepsin H86[P57730](ncbi-p:P57730){#intref0435}CARD182.3624E+081.55114.8027E-051.5916E-03Caspase recruitment domain-containing protein 1887[P04066](ncbi-p:P04066){#intref0440}FUCA16.8916E+081.53245.6178E-051.8278E-03Tissue alpha-L-fucosidase88[O15195](ncbi-p:O15195){#intref0445}VILL3.3877E+081.51117.5024E-052.4006E-03Villin-like protein89[O76041](ncbi-p:O76041){#intref0450}NEBL6.3585E+081.50517.6373E-052.4189E-03Nebulette90[Q9UIV8](ncbi-p:Q9UIV8){#intref0455}SERPINB132.6246E+091.49593.7797E-051.3133E-03Serpin B1391[P31151](ncbi-p:P31151){#intref0460}S100A73.1030E+101.49524.3317E-041.1194E-02Protein S100-A792[Q5T2T1](ncbi-p:Q5T2T1){#intref0465}MPP73.6873E+081.49468.9940E-052.8237E-03MAGUK p55 subfamily member 793[P04792](ncbi-p:P04792){#intref0470}HSPB17.9479E+101.49094.4937E-041.1488E-02Heat shock protein beta-194[P04259](ncbi-p:P04259){#intref0475}KRT6B2.7359E+081.48789.6874E-052.9889E-03Keratin, type II cytoskeletal 6B95[P18510](ncbi-p:P18510){#intref0480}IL1RN1.8987E+091.48224.4462E-051.4872E-03Interleukin-1 receptor antagonist protein96[B4DRX0](uniprotkb:B4DRX0){#intref0485}1.5497E+091.46395.5077E-051.8085E-03highly similar to guanylate binding protein family, member 6 (GBP6)97[Q6UXB2](ncbi-p:Q6UXB2){#intref0490}CXCL175.5635E+081.45381.3440E-044.0037E-03C-X-C motif chemokine 1798[Q92747](ncbi-p:Q92747){#intref0495}ARPC1A4.4174E+081.44131.5382E-044.4758E-03Actin-related protein 2/3 complex subunit 1A99[Q9UN76](ncbi-p:Q9UN76){#intref0500}SLC6A144.3694E+081.43871.5821E-044.5664E-03Sodium- and chloride-dependent neutral and basic amino acid transporter B(0+)100[Q2I377](ncbi-p:Q2I377){#intref0505}3.0828E+081.42481.8970E-045.3883E-03Small proline rich protein101[Q5Y7A7](ncbi-p:Q5Y7A7){#intref0510}HLA-DRB12.1967E+081.41981.9983E-045.5873E-03HLA class II histocompatibility antigen, DRB1-13 beta chain102[Q9C002](ncbi-p:Q9C002){#intref0515}NMES17.4517E+081.40172.3416E-046.4465E-03Normal mucosa of esophagus-specific gene 1 protein103[O43240](ncbi-p:O43240){#intref0520}KLK102.1896E+081.38372.8976E-047.9164E-03Kallikrein-10104[Q9UKR0](ncbi-p:Q9UKR0){#intref0525}KLK122.4196E+081.35004.0703E-041.0712E-02Kallikrein-12105[P26447](ncbi-p:P26447){#intref0530}S100A46.4331E+081.34154.3475E-041.1194E-02Protein S100-A4106[P40394](ncbi-p:P40394){#intref0535}ADH76.0307E+081.30576.2060E-041.5213E-02Alcohol dehydrogenase class 4 mu/sigma chain107[O75841](ncbi-p:O75841){#intref0540}UPK1B5.8669E+081.29896.6380E-041.6161E-02Uroplakin-1b108[Q13938](ncbi-p:Q13938){#intref0545}CAPS2.5889E+081.29526.9632E-041.6614E-02Calcyphosin109[Q8N335](ncbi-p:Q8N335){#intref0550}GPD1L3.8423E+081.27898.1387E-041.8915E-02Glycerol-3-phosphate dehydrogenase 1-like protein110[O60547](ncbi-p:O60547){#intref0555}GMDS4.5212E+081.26009.6618E-042.1612E-02GDP-mannose 4,6 dehydratase111[P10253](ncbi-p:P10253){#intref0560}GAA4.9534E+081.25071.0556E-032.3322E-02Lysosomal alpha-glucosidase112[P27338](ncbi-p:P27338){#intref0565}MAOB2.2924E+081.24611.1069E-032.4156E-02Amine oxidase \[flavin-containing\] B113[P00167](ncbi-p:P00167){#intref0570}CYB5A1.2616E+091.20468.8749E-042.0361E-02Cytochrome b5114[Q6ZNJ1](ncbi-p:Q6ZNJ1){#intref0575}NBEAL23.6960E+081.18082.0022E-033.8320E-02Neurobeachin-like protein 2115[P12074](ncbi-p:P12074){#intref0580}COX6A12.1947E+081.16942.2153E-034.1295E-02Cytochrome c oxidase subunit 6A1, mitochondrial116[Q15067](ncbi-p:Q15067){#intref0585}ACOX16.7813E+081.16452.3280E-034.2947E-02Peroxisomal acyl-coenzyme A oxidase 1117[O95833](ncbi-p:O95833){#intref0590}CLIC31.8996E+091.16351.3201E-032.7559E-02Chloride intracellular channel protein 3118[Q3ZCW2](ncbi-p:Q3ZCW2){#intref0595}LGALSL3.9168E+081.16142.3755E-034.3407E-02Galectin-related protein119[Q9UN36](ncbi-p:Q9UN36){#intref0600}NDRG22.2476E+091.14661.5480E-033.1125E-02Protein NDRG2120[P05120](ncbi-p:P05120){#intref0605}SERPINB21.0883E+091.11981.9863E-033.8221E-02Plasminogen activator inhibitor 2121[P19971](ncbi-p:P19971){#intref0610}TYMP2.3800E+091.08342.7648E-034.9975E-02Thymidine phosphorylase[^2]Table 2Down-regulated proteins in well-differentiated normal human primary bronchial/tracheal epithelial cells compared with un-differentiated cells.Table 2Serial numberUniProtKB AccessionProtein NameMean IntensityLog10 (Ratio)p ValueFDRProtein Description1[P37268](ncbi-p:P37268){#intref0615}FDFT13.0783E+09-2.38247.1064E-162.5434E-12Squalene synthase2[Q9Y617](ncbi-p:Q9Y617){#intref0620}PSAT12.3742E+09-2.33762.0480E-143.6650E-11Phosphoserine aminotransferase3[Q01581](ncbi-p:Q01581){#intref0625}HMGCS14.2580E+09-2.03276.5950E-122.9504E-09Hydroxymethylglutaryl-CoA synthase, cytoplasmic4[P0DJJ0](ncbi-p:P0DJJ0){#intref0630}SRGAP2C1.4731E+09-1.99676.7214E-112.1869E-08SLIT-ROBO Rho GTPase-activating protein 2C5[Q13642](ncbi-p:Q13642){#intref0635}FHL19.6190E+08-1.97351.0290E-129.2067E-10Four and a half LIM domains protein 16A0A024R7D5LDLR1.2463E+09-1.80673.5816E-093.7701E-07Low density lipoprotein receptor (Familial hypercholesterolemia), isoform CRA_b7[Q13509](ncbi-p:Q13509){#intref0640}TUBB31.2541E+09-1.73641.4161E-081.2995E-06Tubulin beta-3 chain8[Q9NR30](ncbi-p:Q9NR30){#intref0645}DDX211.0413E+09-1.71512.1298E-081.8591E-06Nucleolar RNA helicase 29[O00622](ncbi-p:O00622){#intref0650}CYR618.7896E+08-1.70826.3728E-109.5035E-08Protein CYR6110[Q9NRN7](ncbi-p:Q9NRN7){#intref0655}AASDHPPT4.5529E+08-1.68361.1057E-091.3496E-07L-aminoadipate-semialdehyde dehydrogenase-phosphopantetheinyl transferase11[Q8WWM9](ncbi-p:Q8WWM9){#intref0660}CYGB4.6634E+08-1.65252.1998E-092.5397E-07Cytoglobin12[O95864](ncbi-p:O95864){#intref0665}FADS24.4000E+08-1.63972.9108E-093.1569E-07Fatty acid desaturase 213[Q12805](ncbi-p:Q12805){#intref0670}EFEMP13.7486E+08-1.63791.0847E-043.3180E-03EGF-containing fibulin-like extracellular matrix protein 114[O43175](ncbi-p:O43175){#intref0675}PHGDH3.0724E+09-1.54002.3106E-071.5314E-05D-3-phosphoglycerate dehydrogenase15[P46821](ncbi-p:P46821){#intref0680}MAP1B4.1297E+08-1.52763.0452E-048.2566E-03Microtubule-associated protein 1B16[P33993](ncbi-p:P33993){#intref0685}MCM72.3134E+08-1.52443.1372E-048.4108E-03DNA replication licensing factor MCM717[Q9Y2S6](ncbi-p:Q9Y2S6){#intref0690}TMA72.5980E+08-1.52393.1490E-048.4108E-03Translation machinery-associated protein 718[P49023](ncbi-p:P49023){#intref0695}PXN1.1578E+09-1.51917.1610E-073.8832E-05Paxillin19[Q9UMD9](ncbi-p:Q9UMD9){#intref0700}COL17A11.2158E+09-1.50419.2116E-074.9207E-05Collagen alpha-1(XVII) chain20[P08133](ncbi-p:P08133){#intref0705}ANXA64.8577E+09-1.49834.9271E-072.7553E-05Annexin A621[Q14683](ncbi-p:Q14683){#intref0710}SMC1A3.9266E+08-1.48054.6415E-041.1698E-02Structural maintenance of chromosomes protein 1A22[Q6NYC8](ncbi-p:Q6NYC8){#intref0715}PPP1R181.7006E+08-1.47737.5124E-052.4006E-03Phostensin23[P08243](ncbi-p:P08243){#intref0720}ASNS2.2748E+08-1.43856.6961E-041.6193E-02Asparagine synthetase \[glutamine-hydrolyzing\]24[P46087](ncbi-p:P46087){#intref0725}NOP23.5465E+08-1.43616.8331E-041.6413E-02Probable 28S rRNA (cytosine(4447)-C(5))-methyltransferase25[Q03001](ncbi-p:Q03001){#intref0730}DST8.9712E+08-1.41832.6397E-071.7177E-05Dystonin26[P21589](ncbi-p:P21589){#intref0735}NT5E7.6840E+08-1.41672.7252E-071.7417E-055′-nucleotidase27[O60701](ncbi-p:O60701){#intref0740}UGDH7.7732E+08-1.41063.0586E-071.9204E-05UDP-glucose 6-dehydrogenase28[P01583](ncbi-p:P01583){#intref0745}IL1A3.9459E+08-1.40209.1373E-042.0830E-02Interleukin-1 alpha29[P50281](ncbi-p:P50281){#intref0750}MMP143.4994E+08-1.39949.3387E-042.1154E-02Matrix metalloproteinase-1430[P14317](ncbi-p:P14317){#intref0755}HCLS12.3506E+08-1.39839.4278E-042.1221E-02Hematopoietic lineage cell-specific protein31[O00148](ncbi-p:O00148){#intref0760}DDX39A3.4044E+08-1.37971.1010E-032.4156E-02ATP-dependent RNA helicase DDX39A32[Q86V48](ncbi-p:Q86V48){#intref0765}LUZP14.1773E+08-1.37651.1304E-032.4371E-02Leucine zipper protein 133[Q96QD8](ncbi-p:Q96QD8){#intref0770}SLC38A28.5362E+08-1.37066.4406E-073.5463E-05Sodium-coupled neutral amino acid transporter 234[P49736](ncbi-p:P49736){#intref0775}MCM22.1169E+08-1.36291.2641E-032.6931E-02DNA replication licensing factor MCM235[Q8IVT2](ncbi-p:Q8IVT2){#intref0780}MISP2.8957E+08-1.35811.3154E-032.7559E-02Mitotic interactor and substrate of PLK136[Q14566](ncbi-p:Q14566){#intref0785}MCM63.5072E+08-1.35731.3244E-032.7559E-02DNA replication licensing factor MCM637[Q27J81](ncbi-p:Q27J81){#intref0790}INF27.0837E+08-1.32661.4321E-067.1190E-05Inverted formin-238[Q9NX58](ncbi-p:Q9NX58){#intref0795}LYAR8.6688E+08-1.30622.0585E-069.5682E-05Cell growth-regulating nucleolar protein39[Q9H2H9](ncbi-p:Q9H2H9){#intref0800}SLC38A12.3999E+08-1.29742.1423E-034.0355E-02Sodium-coupled neutral amino acid transporter 140[P17812](ncbi-p:P17812){#intref0805}CTPS19.9882E+08-1.27423.2945E-051.1674E-03CTP synthase 141[Q04941](ncbi-p:Q04941){#intref0810}PLP23.2283E+08-1.27262.5998E-034.7231E-02Proteolipid protein 242[P84157](ncbi-p:P84157){#intref0815}MXRA71.8172E+08-1.26047.1016E-041.6832E-02Matrix-remodeling-associated protein 743[O60232](ncbi-p:O60232){#intref0820}SSSCA11.6184E+08-1.25607.4088E-041.7445E-02Sjoegren syndrome/scleroderma autoantigen 144A0A0A6YYF2LAMA36.4962E+09-1.25502.7593E-059.9754E-04HCG1811249, isoform CRA_e45[Q92888](ncbi-p:Q92888){#intref0825}ARHGEF11.7622E+08-1.25287.6439E-041.7881E-02Rho guanine nucleotide exchange factor 146[P31146](ncbi-p:P31146){#intref0830}CORO1A2.0013E+08-1.21281.1158E-032.4202E-02Coronin-1A47[P07942](ncbi-p:P07942){#intref0835}LAMB11.3318E+08-1.20531.1959E-032.5629E-02Laminin subunit beta-148[P35080](ncbi-p:P35080){#intref0840}PFN22.0038E+08-1.19241.3479E-032.7885E-02Profilin-249[Q9Y6A4](ncbi-p:Q9Y6A4){#intref0845}CFAP201.9573E+08-1.18791.4044E-032.8723E-02Cilia- and flagella-associated protein 2050[O00461](ncbi-p:O00461){#intref0850}GOLIM41.6700E+08-1.17301.6080E-033.2150E-02Golgi integral membrane protein 451[Q9NPR2](ncbi-p:Q9NPR2){#intref0855}SEMA4B1.2144E+08-1.16391.7472E-033.4548E-02Semaphorin-4B52[Q14554](ncbi-p:Q14554){#intref0860}PDIA51.6747E+08-1.15461.8978E-033.7015E-02Protein disulfide-isomerase A553[P33992](ncbi-p:P33992){#intref0865}MCM51.8888E+08-1.15381.9124E-033.7015E-02DNA replication licensing factor MCM554[B4DY32](uniprotkb:B4DY32){#intref0870}1.3526E+09-1.14591.9130E-045.3911E-03highly similar to Asparagine synthetase (glutamine-hydrolyzing)55[Q96CT7](ncbi-p:Q96CT7){#intref0875}CCDC1241.1834E+08-1.14372.0924E-033.9833E-02Coiled-coil domain-containing protein 12456[Q96SB4](ncbi-p:Q96SB4){#intref0880}SRPK11.7336E+08-1.12922.3771E-034.3407E-02SRSF protein kinase 157[Q13085](ncbi-p:Q13085){#intref0885}ACACA1.1539E+09-1.07664.6078E-041.1696E-02Acetyl-CoA carboxylase 158[P39748](ncbi-p:P39748){#intref0890}FEN14.5603E+08-1.04881.2811E-043.8530E-03Flap endonuclease 159[P06454](ncbi-p:P06454){#intref0895}PTMA8.2681E+09-1.04665.0925E-041.2745E-02Prothymosin alpha60[P05114](ncbi-p:P05114){#intref0900}HMGN17.5290E+08-1.04041.4455E-044.2406E-03Non-histone chromosomal protein HMG-1461[Q96CX2](ncbi-p:Q96CX2){#intref0905}KCTD128.8738E+08-1.01622.0413E-045.6633E-03BTB/POZ domain-containing protein KCTD1262A0A024R3T8PARP19.8939E+08-0.98991.2938E-032.7400E-02Poly \[ADP-ribose\] polymerase63[Q16222](ncbi-p:Q16222){#intref0910}UAP19.9843E+08-0.98491.3697E-032.8173E-02UDP-N-acetylhexosamine pyrophosphorylase64[P17301](ncbi-p:P17301){#intref0915}ITGA22.0048E+09-0.97781.4842E-033.0181E-02Integrin alpha-265[O43592](ncbi-p:O43592){#intref0920}XPOT5.2138E+08-0.97513.6079E-049.5648E-03Exportin-T66[P0DME0](ncbi-p:P0DME0){#intref0925}SETSIP4.8935E+08-0.96314.2423E-041.1083E-02Protein SETSIP67[Q9UHD1](ncbi-p:Q9UHD1){#intref0930}CHORDC19.7224E+08-0.95521.9133E-033.7015E-02Cysteine and histidine-rich domain-containing protein 168[Q01628](ncbi-p:Q01628){#intref0935}IFITM34.7824E+08-0.94735.2393E-041.3022E-02Interferon-induced transmembrane protein 369[Q9BQL6](ncbi-p:Q9BQL6){#intref0940}FERMT15.0585E+08-0.94455.4389E-041.3425E-02Fermitin family homolog 170[Q13751](ncbi-p:Q13751){#intref0945}LAMB31.3431E+10-0.92772.1612E-034.0498E-02Laminin subunit beta-371[P49321](ncbi-p:P49321){#intref0950}NASP4.8148E+08-0.90878.6662E-042.0010E-02Nuclear autoantigenic sperm protein72[Q15654](ncbi-p:Q15654){#intref0955}TRIP64.6028E+08-0.89401.0450E-032.3231E-02Thyroid receptor-interacting protein 673[P13726](ncbi-p:P13726){#intref0960}F39.1561E+08-0.86411.5165E-033.0665E-02Tissue factor74[P16949](ncbi-p:P16949){#intref0965}STMN18.0051E+08-0.85741.6455E-033.2717E-02Stathmin75[Q8WX93](ncbi-p:Q8WX93){#intref0970}PALLD5.5338E+08-0.85181.7609E-033.4628E-02Palladin76[P27708](ncbi-p:P27708){#intref0975}CAD7.5907E+08-0.83642.1201E-034.0147E-02CAD protein77[B3KS36](uniprotkb:B3KS36){#intref0980}4.7213E+08-0.83192.2366E-034.1475E-02highly similar toribosomal protein L3 (RPL3), transcript variant 2[^3]

3.3. Comparative proteomic analysis {#sec3.3}
-----------------------------------

Identified proteins were sorted using the gene function classification systems GO and KEGG pathways. The number of functional entries in the up/down-regulated protein set were then compared with the functional entries in the entire protein set.

For GO assessment, classification nodes (categories) within 5 steps of the root node were surveyed. The analysis identified 30 Cellular Component categories, e.g., extracellular region (GO:0005576), plasma membrane (GO:0005886) and apical part of cell (GO:0045177); 50 Molecular Function categories, e.g., structural constituent of epidermis (GO:0030280), signaling receptor activity (GO:0038023) and structural molecule activity (GO:0005198); and 199 Biological Process categories, e.g., cell adhesion (GO:0098609), localization of cell (GO:0051674), epithelial cell proliferation (GO:0050673) and regulation of immune system process (GO:0002682), with 94.9% (188/198), 87.4% (173/198) and 91.4% (181/198) differential protein coverage, respectively. [Figure 4](#fig4){ref-type="fig"} shows the enrichment of GO functional entries that are relatively close to the root node.Figure 4Enriched GO categories of up/down regulated proteins in well-differentiated normal human primary bronchial/tracheal epithelial cells compared with un-differentiated cells. Classification nodes that were 1 or 2 steps from the root node are shown. The size of the dot indicates the number of proteins in the up/down regulated protein set. P values were obtained by Fisher\'s test.Figure 4

Fifteen enriched KEGG pathways were detected in this study, including 6 "Metabolism" pathways, 3 "Human disease" pathways, 2 "Organismal system" pathways, 2 "Environmental information processing" pathways, one "Cellular process" pathway, and one "Genetic information processing" pathway ([Figure 5](#fig5){ref-type="fig"}).Figure 5Enriched KEGG pathways of up/down regulated proteins in well-differentiated normal human primary bronchial/tracheal epithelial cells compared with un-differentiated cells. The grey labels identify the highest-order KEGG pathway classification entries. The size of the dot indicates the number of proteins in the up/down protein set. P values were obtained by Fisher\'s test.Figure 5

Query of the STRING database with the 198 up/down-regulated proteins identified 135 (68.18%) proteins with interactions and 256 pairs of interactions. These interactions constituted an integral network with several sets of divided connections ([Figure 6](#fig6){ref-type="fig"}). Six pathways of up/down-regulated proteins were identified with a minimum of four closely linked proteins in the network. Among these pathways, all proteins in the "Retinol metabolism" (ko00830) and "IL-17 signaling pathway" (ko04657) nodes were up-regulated. All proteins in the "Cell cycle" (ko04110) and "DNA replication" (ko03030) nodes were down-regulated. The "ECM-receptor interaction" (ko04512) and "Complement and coagulation cascades" (ko04610) nodes had both up- and down-regulated proteins ([Figure 6](#fig6){ref-type="fig"}).Figure 6Protein-protein interaction network of up/down regulated proteins in well-differentiated normal human primary bronchial/tracheal epithelial cells compared with un-differentiated cells. Pairs of proteins with interactions are linked with lines. The thickness of the line represents the magnitude of the combined interaction score provided by STRING. Interaction scores ranged between 0.400 and 0.999. Colored blocks were assigned when a minimum of four proteins fell into the same KEGG pathway.Figure 6

3.4. Up/down-regulated protein confirmation by LC-PRM/MS {#sec3.4}
--------------------------------------------------------

Protein expression levels of five differentially regulated proteins associated with epithelial structure formation (SCEL (O95171), KRT10 (A0A1B0GVI3) and POF1B (Q8WVV4)) ([@bib33]), cell cycle (CLIC3 (Q8IVT2)) ([@bib37]), and immunity (S100A8 (P05109)) ([@bib39]) were verified by label-free LC-PRM/MS analysis. Experiments were performed with 12 peptides of the 5 target proteins in WD and UD cells. The relative levels of target proteins were calculated based on the corresponding peptides ([Table 3](#tbl3){ref-type="table"}). Consistent with previous proteomics results, four up-regulated proteins (SCEL, S100A8, KRT10, POF1B) and one down-regulated protein (CLIC3) were identified in WD cells compared with UD cells.Table 3LC-PRM/MS confirmation of up/down-regulated proteins in well-differentiated normal human primary bronchial/tracheal epithelial cells compared with un-differentiated cells.Table 3UniProtKB AccessionProtein nameProtein descriptionMean content in WD cellsMean content in UD cellsContent ratio (WD/UD)P value[O95171](ncbi-p:O95171){#intref0985}SCELSciellin6.09740.106957.03710.0334[P05109](ncbi-p:P05109){#intref0990}S100A8Protein S100-A8296.13614.635363.88690.0167A0A1B0GVI3KRT10Keratin, type I cytoskeletal 100.11590.009212.63860.0089[Q8WVV4](ncbi-p:Q8WVV4){#intref0995}POF1BProtein POF1B1.69240.124813.56040.0027[Q8IVT2](ncbi-p:Q8IVT2){#intref1000}CLIC3Mitotic interactor and substrate of PLK10.35171.49830.23470.0005[^4]

Supporting data from this study are available in supplementary materials ([Tables S1 and S2](#appsec1){ref-type="sec"}).

4. Discussion {#sec4}
=============

Human airway epithelium is a primary barrier to environmental exposures and signals to other cell types within the context of the epithelial mesenchymal trophic unit ([@bib16]). This layer plays a key role in airway remodeling and inflammation. WD cells are an important *in vitro* model for human airway epithelium which have been used in gene therapy studies, host defense studies, gene expression analysis, preclinical drug development, airborne toxicant studies and bio-defense model development. WD cells can be derived by culturing UD cells at an ALI ([@bib13]). These *in vitro* derived WD cells exhibit polarized epithelium with good barrier function (transepithelial resistance), secretory phenotype (mucin secretion) and ciliogenesis, much like epithelial cells *in vivo* ([@bib16]; [@bib18]). The differentiation of UD cells to WD cells involves down and up regulation of multiple genes and changes in cellular protein composition. To understand the protein profile of WD cells, we performed label-free LC-MS/MS analysis comparing protein patterns of UD and WD cells.

In this study, 33 transwell inserts of WD cells were divided into 3 samples for LC-MS/MS analysis. The mixture of WD cells in one sample was used to reduce error between experimental samples. We confirmed that cells were well-differentiated by testing TEER value (\>1,000 Ω cm^2^) and expression of the biomarkers ZO-1 and β-tubulin IV ([Figure 1](#fig1){ref-type="fig"}). Proteins differentially expressed in WD cells compared with UD cells were identified by label-free LC-MS/MS and confirmed by LC-PRM/MS ([Table 3](#tbl3){ref-type="table"}).

A total of 3,579 proteins were identified in the six samples. Principal components of WD and UD cells exhibited considerable separation ([Figure 2](#fig2){ref-type="fig"}), suggesting substantial difference between the two cell types. Our analyses identified 198 proteins that were significantly different between the two cell types ([Figure 3](#fig3){ref-type="fig"}), including 121 up-regulated and 77 down-regulated proteins in WD cells ([Table 1](#tbl1){ref-type="table"}, [Table 2](#tbl2){ref-type="table"}). GO analysis of the differentially expressed proteins classified the proteins into structure formation of epithelium, cell cycle and immunity ([Figure 4](#fig4){ref-type="fig"}). Membrane-associated proteins were heterogeneous, including plasma membrane (GO: 0005886), and extracellular region (GO: 0005576) proteins ([Figure 4](#fig4){ref-type="fig"}, [Table 1](#tbl1){ref-type="table"}, [Table 2](#tbl2){ref-type="table"}) with a myriad of functions, e.g. structure formation (e.g. SPRR1B (P22528), SPRR2D (P22532)) ([@bib46]), signal transduction (e.g. CD74 (P04233)) ([@bib23]), substance transport (e.g. GPD1L (Q8N335)) ([@bib54]), and immune recognition (e.g. HLA-DRB1 (Q5Y7A7)) ([@bib32]). These differentially expressed proteins could be of great significance in understanding the physiological functions of airway epithelium. In addition, the results of the current study provides important candidate proteins that may be associated with selective infection of WD cells versus UD cells, e.g. human bocavirus ([@bib38]).

Six of the 15 enriched KEGG pathways, "Retinol metabolism", "IL-17 signaling pathway", "Complement and coagulation cascades", "ECM-receptor interaction", "Cell cycle", and "DNA replication" had a minimum of four closely linked differentially expressed proteins (Figures [5](#fig5){ref-type="fig"} and [6](#fig6){ref-type="fig"}). Of these, the highest EF was observed in the down-regulated minichromosome maintenance (MCM) proteins (GO: 0042555) MCM7, MCM5, MCM2 and MCM6 ([Table 2](#tbl2){ref-type="table"}, [Figure 4](#fig4){ref-type="fig"}). These proteins have been reported to contain an ATPase motif ([@bib9]), and are important in DNA replication and cell cycle ([Figure 6](#fig6){ref-type="fig"}). These proteins may therefore contribute to the low proliferation levels of WD cells ([@bib18]; [@bib28]).

Four proteins (ADH7, DHRS9, SDR16C5, ALDH1A1) in the retinol metabolism pathway were up-regulated in WD cells ([Table 1](#tbl1){ref-type="table"}, [Figure 6](#fig6){ref-type="fig"}). Up-regulation of retinol dehydrogenase activity could enhance retinoic acid production ([@bib24]). Retinoic acid regulates a variety of genes, plays important roles in cell growth, differentiation, and organogenesis ([@bib3]; [@bib5]), and is important for mucosal immunity regulation ([@bib34]; [@bib44]).

Four proteins (S100A7, S100A8, S100A9, LCN2) in the IL-17 signaling pathway were also up-regulated in WD cells ([Table 1](#tbl1){ref-type="table"}, [Figure 6](#fig6){ref-type="fig"}). S100A7, S100A8 and S100A9 are calcium- and zinc-binding proteins which play a prominent role in the regulation of inflammatory processes and immune response. These proteins can induce neutrophil chemotaxis and adhesion ([@bib29]; [@bib39]). LCN2 is an iron-trafficking protein involved in multiple processes, e.g. apoptosis, innate immunity and renal development ([@bib4]; [@bib43]; [@bib57]). Up-regulation of the four IL-17 pathway proteins could increase antimicrobial activity of WD cells.

The other two KEGG pathways with four or more closely linked differential proteins were ECM-receptor interaction and complement and coagulation cascades (Figures [5](#fig5){ref-type="fig"} and [6](#fig6){ref-type="fig"}). The presence of up- and down-regulated proteins in both these pathways indicates that WD cells have significantly different cell junction, extracellular matrix composition, and immune response compared with UD cells ([@bib27]; [@bib30]; [@bib45]).

The current study does have some limitations. First, human respiratory epithelium is complex exhibiting large variation in different regions of the tissue. The current study evaluated bronchial/tracheal epithelial cells. Second, cells from one donor were used for all evaluations in the current study. Cells from different individuals may have the potential to change results. Despite these considerations, this study provides a global proteomic profile of WD and UD cells. These results provide insights about differential protein profiles in un-differentiated and well-differentiated bronchial/tracheal epithelial cells and can help future studies.

5. Conclusions {#sec5}
==============

WD cells are an important *in vitro* human airway epithelial model that can be derived by culturing UD cells at an air-liquid interface. In this work, we analyzed the proteomic profiles of WD and UD cells. A total of 3,579 proteins were identified in WD and UD cells. Of these, 198 proteins were found to be differentially expressed, with 121 proteins up-regulated and 77 proteins down-regulated in WD cells compared with UD cells. Most of the differentially expressed proteins were enriched in categories related to structure formation of epithelium, cell cycle, and immunity. This study provides the protein profiles of WD and UD cells increasing knowledge of proteins associated with human airway epithelium.
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